|
Virtual Meetings 2022
Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR MutationFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Pasi A Jänne, MD, PhD Director, Lowe Center for Thoracic Oncology Professor of Medicine, Harvard Medical School Director, Robert and Renée Belfer Center for Applied Cancer Sciences Director, Chen-Huang Center for EGFR-Mutant Lung Cancers Dana-Farber Cancer Institute Boston, Massachusetts Joel W Neal, MD, PhD Associate Professor of Medicine Division of Oncology, Department of Medicine Stanford Cancer Institute Stanford University Palo Alto, California Lecia V Sequist, MD, MPH Director, Center for Innovation in Early Cancer Detection Massachusetts General Hospital Cancer Center The Landry Family Professor of Medicine Harvard Medical School Boston, Massachusetts SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. Agenda
MODULE 1: Therapeutic Selection for Patients with Localized Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation MODULE 2: Current and Future Management of Metastatic NSCLC with an EGFR Mutation MODULE 3: Available Therapeutic Strategies for Patients with NSCLC Harboring an EGFR Exon 20 Insertion Mutation
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Jänne — Consulting Agreements: AbbVie Inc, ACEA Biosciences Inc, Accutar Biotech, Allorion Therapeutics, Araxes Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Ignyta Inc, Kura Oncology, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Novartis, Nuvalent, Pfizer Inc, Sanofi, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Transcenta, Voronoi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Labcorp for postmarketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp. Dr Neal — Advisory and Consulting Roles: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Calithera Biosciences, D2G Oncology Inc, Exelixis Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Sanofi, Surface Oncology, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Nektar, Novartis, Takeda Pharmaceuticals USA Inc. Dr Sequist — Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Delfi Diagnostics, Genentech, a member of the Roche Group, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.SURVEY PARTICIPANTS — David Planchard, MD, PhD — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Samsung Bioepis. Gregory J Riely, MD, PhD — Contracted Research: Genentech, a member of the Roche Group, Lilly, Merck, Mirati Therapeutics Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Novartis. David R Spigel, MD — Consulting Agreements (to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Curio Science, EMD Serono Inc, Evidera, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Molecular Templates, Novartis, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, EMD Serono Inc, Evelo Biosciences Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Grail Inc, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Molecular Partners, Molecular Templates, Nektar, Neon Therapeutics, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, UT Southwestern Medical Center, Verastem Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC. |